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SHO KANZAKI,1,2 TIMO STÖVER,3 KOHEI KAWAMOTO,1,4 DIANE M. PRIESKORN,1
RICHARD A. ALTSCHULER,1 JOSEF M. MILLER,1,5 AND YEHOASH RAPHAEL1*
1Kresge Hearing Research Institute, University of Michigan, Ann Arbor, Michigan 48109-0648
2Department of Otolaryngology, Keio University, Shinjuku, Tokyo 160-0016, Japan
3ENT Clinic of the Medizinischen Hochschule Hannover, 30625 Hannover, Germany
4Department of Otolaryngology, Kansai Medical University, Moriguchi, Osaka 570-8506, Japan
5Department of Otolaryngology, Karolinska Institute, Stockholm, S 17176 Sweden
ABSTRACT
As with other cranial nerves and many CNS neurons, primary auditory neurons degenerate
as a consequence of loss of input from their target cells, the inner hair cells (IHCs). Electrical
stimulation (ES) of spiral ganglion cells (SGCs) has been shown to enhance their survival. Glial
cell line-derived neurotrophic factor (GDNF) has also been shown to increase survival of SGCs
following IHC loss. In this study, the combined effects of the GDNF transgene delivered by
adenoviral vectors (Ad-GDNF) and ES were tested on SGCs after first eliminating the IHCs.
Animal groups received Ad-GDNF or ES or both. Ad-GDNF was inoculated into the cochlea of
guinea pigs after deafening, to overexpress human GDNF. ES-treated animals were implanted
with a cochlear implant electrode and chronically stimulated. A third group of animals received
both Ad-GDNF and ES (GDNF/ES). Electrically evoked auditory brainstem responses were
recorded from ES-treated animals at the start and end of the stimulation period. Animals were
sacrificed 43 days after deafening and their ears prepared for evaluation of IHC survival and SGC
counts. Treated ears exhibited significantly greater SGC survival than nontreated ears. The
GDNF/ES combination provided significantly better preservation of SGC density than either
treatment alone. Insofar as ES parameters were optimized for maximal protection (saturated
effect), the further augmentation of the protection by GDNF suggests that the mechanisms of
GDNF- and ES-mediated SGC protection are, at least in part, independent. We suggest that
GDNF/ES combined treatment in cochlear implant recipients will improve auditory perception.
These findings may have implications for the prevention and treatment of other neurodegenera-
tive processes. J. Comp. Neurol. 454:350–360, 2002. © 2002 Wiley-Liss, Inc.
Indexing terms: gene transfer; growth factors; spiral ganglion; cochlea; guinea pig; cochlear
implant
Cranial nerve degeneration secondary to denervation is
a common finding in the nervous system (Springer and
Kitzman, 1998). Cochlear inner hair cells (IHCs) normally
provide excitatory activation of the auditory nerve, the
VIII cranial nerve. Following the loss of IHCs from
trauma or degenerative disease, auditory neurons degen-
erate (Otte et al., 1978; Webster and Webster, 1981; Shep-
herd et al., 1983; Sutton, 1983; Jyung et al., 1989; Leake et
al., 1991; Nadol and Hsu, 1991). Absence of both excita-
tory activity and chemical survival factors has been im-
plicated in the loss of auditory neurons (Bohne and Har-
ding, 1993) following deafness. Reintroducing excitation
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to the auditory nerve following IHC loss using chronic
cochlear electrical stimulation (ES) has been shown to
greatly reduce the deafness-related loss of spiral ganglion
cells (SGCs) (Lousteau, 1987; Hartshorn et al., 1991;
Leake et al., 1991; Miller et al., 1997; Mitchell et al.,
1997), although there have also been reports that ES is
not always protective (Shepherd et al., 1994; Araki et al.,
1998; Li et al., 1999). The mechanism through which ES
enhances SGC survival is not completely understood. In
vitro studies on explanted SGC neurons have shown a
depolarization-induced enhancement of SGC survival that
is mediated by L-type voltage gated Ca2 channels (He-
garty et al., 1997). It has recently been shown in vivo that
blocking L-type voltage-gated Ca2 channels eliminates
the protective effective of ES (Miller, 2001), supporting
this mechanism for chronic ES-induced survival of SGC
following deafness. These observations indicate that ES
may enhance cell survival by maintaining intracellular
Ca2 levels within a physiological range.
Chronic perilymphatic infusion of chemical survival fac-
tors has also been shown to reduce SGC loss following loss
of IHC. Effective survival factors include neurotrophins
(Ernfors et al., 1996; Staecker et al., 1996; Miller et al.,
1997), GM1 ganglioside (Walsh and Webster, 1994), and
the neurotrophic factor glial cell line-derived neurotrophic
factor (GDNF; Ylikoski et al., 1998). Introduction of
GDNF by adenoviral vector has also been shown to en-
hance SGC survival following deafness (Yagi et al., 2001).
It is not known whether the pathways by which the
different survival factors, including ES, achieve enhanced
SGC survival are independent or overlapping. A combina-
tion of the neurotrophins brain-derived neurotrophic fac-
tor (BDNF) and neurotrophin 3 (NT3) was shown to have
additive survival effects in vitro (Mou et al., 1997, 1998);
however, an in vivo study demonstrated that a “cocktail”
of chemical survival factors was no more effective than
when they were applied singly (Miller et al., 1997). In the
present in vivo study, we examined the effects of the
combined application of a chemical survival factor and ES
compared with the effects of a single protective factor (ES
or chemical survival factor). GDNF was used as the chem-
ical survival factor and was applied via an adenoviral
vector.
GDNF, a member of a relatively new family of trophic
factors related to the transforming growth factor- super-
family, was initially isolated and cloned as a factor pro-
duced by B49 rat glial cells with pronounced trophic ef-
fects on cultured fetal rat midbrain dopamine neurons
(Lin et al., 1993, 1994). GDNF is synthesized by many cell
types throughout the body and affects the development
and survival of a diverse set of neuronal and nonneuronal
cells (Henderson et al., 1994; Trupp et al., 1995; Moore et
al., 1996; Pichel et al., 1996; Sanchez et al., 1996; Buj-
Bello et al., 1997).
In the normal mammalian inner ear, GDNF mRNA is
expressed in developing outer hair cells (OHCs) and IHCs as
well as in mature IHCs (Ylikoski et al., 1998). The GDNF
receptor GFR1 (formerly GDNFR) is expressed in SGCs
(Ylikoski et al., 1998; Stöver et al., 2000, 2001). GDNF has
been shown to be up-regulated after trauma to the inner ear
(Nam et al., 2000) and to enhance SGC survival after IHC
loss (Miller et al., 1997; Yagi et al., 2001). The protective
effects of GDNF on SGCs are mediated by binding and
activation of the two GDNF receptors. Once activated,
GDNF is thought to promote cell survival through intracel-
lular signaling via the cAMP responsive element-binding
(CREB) and phosphatidylinositol 3-kinase (PI3K) pathways
(Xing et al., 1998; Feng et al., 1999; Hayashi et al., 2000).
However, the exact signaling cascade is not completely clear
at present.
There are several ways to introduce therapeutic mole-
cules such as growth factors into the inner ear. One ap-
proach is to inoculate the protein itself. The main disad-
vantages of this approach are degradation by proteases,
requiring continuous administration, and potential im-
mune response against the protein. Gene transfer is an
alternative, in which the specific gene is incorporated into
cells, leading to the synthesis of the required protein (Bar-
kats et al., 1998). This is especially attractive when the
necessary protein is a secreted and diffusible molecule, as
is the case with growth factors; it is particularly appropri-
ate in organs such as the eye or the inner ear, where the
gene product can be secreted directly into the fluid bathing
the target cells.
Delivery of GDNF by an adenovirus vector has been
tested for several neurological applications. For instance,
administration of Ad-GDNF into the vitreous body of rat
eyes enhanced survival of axotomized retinal ganglion
cells (Schmeer et al., 2002). In another study, Ad-GDNF
was injected into muscle tissue of amyotrophic lateral
sclerosis model mice. Survival of motor neurons in treated
muscles was significantly increased compared with con-
trols (Manabe et al., 2002).
The cochlea possesses several advantages as a target
organ for gene transfer. Although it is encased in the
temporal bone, inoculation with vectors is technically fea-
sible. The otic capsule isolates the inner ear fluids and
tissues and reduces the spread of viral particles and se-
creted protein to adjacent tissues. The endolymphatic duct
and the cochlear aqueduct, which connect the cochlea to
other areas, have a very limited flow. The cochlear fluids
allow diffusible particles, such as viruses or proteins, to
disperse rapidly throughout the cochlea and facilitate
their ready access to the SGCs. Adenovirus vectors have
been used for gene transfer into several organs, including
the inner ear, where the most efficiently transduced cells
are the mesothelial cells lining the perilymphatic space,
especially in the scala tympani (Stöver et al., 1999; Yagi et
al., 1999; Suzuki et al., 2000). It is possible, therefore, to
transduce these cells with a gene encoding a secreted
growth factor, which leads to overexpression and secretion
of the transgenic protein into the perilymph, making it
available to the SGCs. This strategy has been successfully
used with Ad-GDNF to enhance survival of denervated
SGCs (Yagi et al., 2001).
The goal of this experiment was to determine the com-
bined effects of ES and virally mediated GDNF overex-
pression on the survival and health of SGCs in ototoxically
deafened guinea pigs. The results demonstrate that the
combined protection afforded by GDNF and ES is greater
than that of either of the two alone.
MATERIALS AND METHODS
Animal groups
Twenty-four pigmented guinea pigs (240–380 g) were
used. Animals were obtained from an outbred colony (Elm
Hill Breeding Labs, Chelmsford, MA). All animal experi-
ments were approved by the University of Michigan Com-
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mittee for the Use and Care of Animals and were performed
using accepted veterinary standards. The University of
Michigan is fully accredited by the Association for Assess-
ment and Accreditation of Laboratory Animal Care Interna-
tional.
Animals were divided into three treatment groups: ES
alone (N  7), GDNF transgene delivered by adenoviral
vectors (Ad-GDNF) alone (N  7), or ES  Ad-GDNF (N 
8). The implant and the Ad-GDNF were placed in the left
ear, whereas the right ear served as a control. In addition,
two normal (nondeafened) guinea pigs were used in the
immunocytochemistry experiments to detect GDNF in the
cochlea. Ad-GDNF was administered in these animals as
in the Ad-GDNF alone group.
On day 1, a combination of ototoxic drugs was system-
ically infused to eliminate most cochlear IHCs and OHCs
bilaterally. On day 5, deafening was verified with acous-
tically evoked auditory brainstem response audiometry
(aABR), and then aseptic surgery was performed to place
a cochlear implant electrode into the inner ear and/or
inoculate the cochlea with adenovirus vector containing
the human GDNF insert (Ad-GDNF). The recombinant
adenovirus vector has been previously described (Lapchak
et al., 1997). In animals that received ES, the stimulation
started on day 8 following a baseline electrical ABR
(eABR), to ensure electrode function, and continued for 36
days. All animals were euthanized on day 44 following
eABR measurement to reconfirm electrode function.
Acoustic ABRs
Baseline and postdeafening (day 5) aABRs were per-
formed on all subjects. Animals were anesthetized with
xylazine (10 mg/kg IM) and ketamine HCl (40 mg/kg IM)
and placed in a soundproof room. Neural responses were
recorded with subcutaneous recording needle electrodes
placed at the vertex (active) against a reference placed at
the midline of the skull approximately 2 cm anterior to
bregma and in the thigh (ground). Computer-generated
alternating polarity pulses (100 sec duration, 50 pps)
were delivered to a transducer positioned in the ear canal.
Clicks were calibrated with a Bruel and Kjaer condenser
microphone relative to an SPL peak-to-peak equivalent.
Stimulus-locked electrophysiological activity was aver-
aged for 1,024 samples for 7.7 msec following stimulation.
Stimuli were provided at various intensities to determine
threshold, which was defined as the lowest stimulus in-
tensity that evoked at least a 0.2 V (peak-to-peak, with a
latency of 1.6–3.2 msec) replicable waveform as previ-
ously described (Mitchell et al., 1997). Animals were re-
quired to have a baseline aABR threshold less than or
equal to 50 dB and a postdeafening aABR threshold shift
greater than or equal to 60 dB SPL.
Electrically evoked ABRs
Animals with electrodes were anesthetized for eABRs
on days 8 and 44. Neural responses were recorded from
epidural recording screws positioned at vertex (active),
midline (reference), and ipsilateral to implant (ground).
Two thousand forty-eight responses to 50-sec computer-
generated monophasic current pulses, presented at 50
pulses/second with an alternating polarity on each presen-
tation, were averaged and analyzed in 5-A steps near
threshold. Threshold was determined by visual inspection
of the responses and defined as the lowest intensity level
at which a clear replicable waveform was visible in the
evoked trace. For inclusion in this study, subjects were
required to demonstrate thresholds of less than 100 A at
the beginning and end of the stimulation period.
Deafening procedure
On day 1, animals were injected with a single dose of
kanamycin (400 mg/kg SC). Two hours later, the animals
were anesthetized as described above and prepared for
cannulation of the jugular vein, as previously described
(West et al., 1973), and infused with ethacrynic acid (EA;
40 or 50 mg/kg IV). The temporal pattern of SGC degen-
eration and the density of SGCs in the normal guinea pig
inner ear have previously been described (Jyung et al.,
1989).
Adenoviral vectors
Replication-deficient recombinant adenoviruses were
based on the human adenovirus serotype 5 from which
three transcriptional regions (E1A, E1B, and a portion of
E3) have been deleted (Lapchak et al., 1997). The vector
contained the human GDNF gene driven by the cytomeg-
alovirus (CMV) immediate promoter. Viral suspensions in
10% glycerol were kept at –80°C until thawing for use.
Viral administration and/or electrode
implant procedure
On day 5, animals were anesthetized with ketamine and
xylazine as described above. In addition, chloramphenicol
sodium succinate (30 mg/kg IM) was administered as a
prophylactic antibiotic, and 0.5 ml of 1% lidocaine HCl
was injected SC for local anesthesia. The middle ear was
exposed via the postauricular approach. Under an operat-
ing microscope, a small fenestra was made with a sharp
probe in the otic capsule at the base of the cochlea. In the
group that received Ad-GDNF, a 100-l Hamilton syringe
attached to a vinyl cannula with a fine polyimide tip was
used to slowly inject 5 l of an isotonic adenoviral sus-
pension (approximate concentration of 1010 adenoviral
particles/ml in sterile normal Ringer’s solution) into the
scala tympani, as previously described (Prieskorn et al.,
1999; Stöver et al., 1999). Ten minutes after inoculation,
the cannula was removed, and the fenestra was covered
with a small piece of fascia that adhered to the otic cap-
sule. The bulla defect was sealed with carboxylate cement
(Durelon ESPE America, Norristown, PA). Dexon adsorb-
able suture was used for the subcuticular closure, and the
skin was closed with nylon sutures.
With respect to cochlear implants, prior to implanta-
tion, each stimulating electrode surface was activated to a
stable minimal impedance value (2–5 k) using cyclic
voltometry (–0.9 to 0.5 V) for 30 minutes at 3 Hz (trian-
gular wave) in saline. Epidural recording electrodes were
placed at the vertex (1 cm posterior to bregma), midline (2
cm anterior to bregma), and ipsilateral to the parietal
bone (1 cm lateral to bregma). A restraint bolt (to secure
the portable stimulator) was fastened over bregma by
three self-tapping screws. Methyl methacrylate was used
to cement the recording electrodes, restraint bolt, and
electrode base to the skull. Animals were implanted via
the postauricular approach described above, with a single
ball (250 m) electrode constructed from 90% platinum-
10% iridium (Pt-Ir) wire (76 m in diameter) inserted
approximately 3 mm into the scala tympani through the
round window membrane. In addition to the stimulating
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electrode, an uninsulated Pt-Ir return electrode (130 m)
was placed in the middle ear. The ear was closed as
described above (Mitchell et al., 1997). In the group of
animals that received both Ad-GDNF and ES, the virus
was injected first, followed by electrode implantation. To
prevent leakage of inner ear fluid and viral suspension,
the round window membrane was covered with fascia.
ES
On day 8, after eABR assessment, all implanted ani-
mals began continuous pulsatile ES via a wearable stim-
ulator that was plugged into the electrode connector. The
construction and performance details of this stimulator,
custom made at the Kresge Hearing Research Institute,
were previously described (Mitchell et al., 1997). Contin-
uous stimulation (100 A peak, 100 sec/phase, 250 Hz)
was provided for 36 days at a 40% duty cycle (400 sec on,
600 sec off). The parameters for ES were selected to
accomplish optimal protection of the SGC population, as
empirically determined in guinea pigs (Mitchell et al.,
1997). These parameters also represent a typical on time
for an average implant user among cochlear implant pa-
tients.
Tissue processing and cell counting
Forty-three days after deafening, after eABR measure-
ment, the animals were deeply anesthetized, perfused in-
tracardially with 2.5% glutaraldehyde, and decapitated.
The temporal bones were removed for histological evalu-
ation. Tissues were postfixed in 2.5% glutaraldehyde for
2–3 hours. To shorten the decalcification time, the otic
capsule was trimmed, leaving the modiolar bony core with
the attached spiral organ of Corti. Cochlear tissues were
continuously agitated during the decalcification period (2
days in 1 liter of 4% EDTA with 0.25% glutaraldehyde).
Tissues were then dehydrated in a series of increasing
ethanol concentrations and embedded in JB-4 (Electron
Microscopy Scientific, Washington, PA). Sections were ob-
tained at a near-midmodiolar plane (1 m thickness).
Every thirtieth section was collected on a glass slide,
stained with Paragon, and coverslipped with Permount
(Fisher Scientific, Pittsburgh, PA).
In total 10 sections were collected from each cochlea.
From these 10 sections, five slides were chosen randomly
for counting and statistical analysis. If a low-quality (folds
in the plastic) section was among those selected, it was
replaced by another randomly selected section. In the
guinea pig cochlea, midmodiolar sections include seven or
eight regions of Rosenthal’s canal (Fig. 1). Frequently, the
upper Rosenthal’s canals are inseparable. Therefore, the
number of SGCs was assessed in six regions (A–F). All
neurons with a discernible nucleus present in the section
were counted. SGC density (SGC number/10,000 m2)
was calculated using a Meta-Morph computerized image-
analysis system (Yagi et al., 2001). The entire area of
Rosenthal’s canal in each counted section was circled for
the purpose of area calculation (performed by the soft-
ware). The boundaries of the canal were drawn at the
interface between the bone and the soft tissue within
Rosenthal’s canal. After counting five sections of each
cochlea, the average value of the SGC density was calcu-
lated for each cochlea. SGC density was analyzed using
repeated-measures ANOVA, and post hoc paired com-
parisons were made with Newman-Keuls multiple-
comparisons test. An unpaired Student’s t-test was used
to evaluate the statistical significance of differences be-
tween the right and the left ears of each of the groups. P 
0.05 was considered significant.
Immunohistochemistry
To test the expression of Ad-GDNF and its ability to
synthesize GDNF in the cochlea, we obtained frozen sec-
tions and performed immunocytochemistry using GDNF-
specific antibodies on two normal animals inoculated with
Ad-GDNF. Guinea pigs were deeply anesthetized and per-
fused with 4% paraformaldehyde in phosphate-buffered
saline (PBS), pH 7.4, through the aorta. After removal of
the temporal bones, inner ear tissues were immersed in
fixative for 1 hour. The specimens were decalcified in 4%
EDTA in PBS for 1 week and then immersed in 30%
sucrose (in PBS) overnight. Samples were then placed in a
vacuum for 30 minutes for embedding in OCT and frozen
in ethanol and dry ice, as previously described (Whitlon et
al., 2001). The frozen tissue blocks were sectioned at 10
m using a Leica CM3000 cryostat. Sections were air
dried for 2 hours, permeabilized in 0.3% Triton X-100 for
10 minutes, and then incubated in a polyclonal anti-
GDNF antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) for 60 minutes, rinsed in buffer, and incubated with
rhodamine-conjugated goat anti-rabbit secondary anti-
body (Jackson Immunoresearch Laboratories, West
Grove, PA) diluted 1:100 for 30 minutes. After a final
rinse, sections were mounted on microscope slides with
Crystal/Mount. The negative control was the right side
(not inoculated with the Ad-GDNF). Samples were ana-
lyzed and photographed with a Leica DMRB epifluores-
cence microscope on Kodak Ektachrome 200 film. Adobe
Photoshop software was used to generate figures.
Fig. 1. Schematic drawing showing a midmodiolar cross section of
the guinea pig cochlea as it was sectioned, depicting the regions of
Rosenthal’s canal used for SGC counts. The lower basal cochlear turn
(high-frequency detection area) is in region A and the apical-most
area (low-frequency detection) is in region F.




To determine the efficacy of Ad-GDNF inoculation-
mediated GDNF expression in the cochlea, vector-treated
ears and control ears were prepared for immunocytochem-
istry with GDNF-specific antibodies. In inoculated ears,
the mesothelial cells demonstrated strong positive immu-
nofluorescence (Fig. 2A). SGCs were also positive for the
GDNF antibody in the inoculated ear (Fig. 2B), whereas in
control ears the level of staining in these cells was much
lower (Fig. 2C). GDNF immunoreactivity in Figure 2
shows the basal cochlear turn (region B). SGCs and me-
sothelial cells in higher cochlear turns were also immuno-
reactive with the GDNF antibody (data not shown).
Elimination of hair cells
To mimic the sensorineural deafness caused by degen-
eration of the IHCs, it was necessary to eliminate these
cells. A combination of kanamycin with EA was used, as
previously described (West et al., 1973). Animals had to
have a threshold shift from normal baseline greater than
60 dB measured by click-ABR to be included in the study.
The cochlea of such animals typically has no surviving
IHCs in the lower three turns (Fig. 3A,B). Occasional
surviving IHC are seen in the apical turn, which was not
used in counts for this study.
eABRs
eABR results demonstrate that the implants were func-
tional in all subjects receiving ES. All animals had an
eABR threshold of less than 100 A throughout the study.
There was no significant difference in average eABR
threshold between the ES and the GDNF/ES groups. On
average, eABR thresholds decreased over the course of the
study by approximately 10% (Table 1).
Fig. 2. Cryosections of the cochlea stained with a GDNF-specific
antibody and viewed by immunofluorescence, showing the mesothelial
cells (A) and the spiral ganglion (B) in a left ear inoculated with
Ad-GDNF and the spiral ganglion of a control (right) ear (C). A: Me-
sothelial cells that line the perilymphatic fluid space (arrowhead)
exhibit GDNF-specific immunolabeling (p). B: Within Rosenthal’s ca-
nal, the cell bodies of SGCs are positive for GDNF antibody. C: Neu-
rons are negative for GDNF. A small amount of immunoreactivity is
detected in the Schwann cells surrounding SGCs. Scale bar  100 m.
Fig. 3. Plastic sections of the organ of Corti in the basal turn of a
cochlea from guinea pigs sacrificed 43 days after treatment with
kanamycin and 40 mg EA (A) or 50 mg EA (B). In these animals, the
entire populations of OHCs and IHCs are missing. In place of the hair
cells, expanded supporting cells and scar tissue are detected. The
presumed site where IHCs normally reside is denoted by the arrow-
head. Scale bar  25 m.
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SGC survival in the ES group
The influence of chronic ES and GDNF on the survival
of SGC is illustrated in Figure 4. Across the cochlear
turns, the density of SGCs in the treated ear was higher
than that in the nontreated ear. This difference was sig-
nificant at the P  0.05 level in regions A, B, and D (Fig.
4A). The better effect of ES to the region of the electrode
(first turn) is consistent with the restricted spread of cur-
rent expected at this stimulation level and was observed
in our previous studies (Mitchell et al., 1997) as well as
those from other laboratories (Leake et al., 1992).
SGC survival in the GDNF group
Ears inoculated with Ad-GDNF exhibited robust protec-
tion of the treated (left) ears compared with the control
(right) ears. The protective influence of GDNF was signif-
icant (P  0.05) in all cochlear turns (Fig. 4B). Although
the significant protective effect was observed throughout
the length of the cochlea, it was somewhat greater in the
base, which is consistent with the previous finding of the
density of distribution of viral vectors (Stöver et al., 1999).
SGC survival in the combined
GDNF/ES group
In GDNF/ES-treated animals, the SGC survival was
significantly greater in the treated vs. control ears
throughout the cochlea (Fig. 4C).
Comparison across groups
Because the best effect of ES on nerve survival is noted
in the basal areas of the cochlea (Fig. 5, regions A and B),
it should be most illuminating to assay the relative effec-
tiveness of the three treatments in regions A and B (com-
bined). Figure 5 shows the SGC density in regions A and
B in the three groups, ES alone, GDNF alone, and GDNF/
ES, and their contralateral nontreated control ears. There
was little difference across the nontreated ears. However,
the difference between the treated and nontreated (con-
trol) ears of each group was significant at the P  .05 level
(Fig. 5). Treatment with GDNF  ES was significantly
more effective than treatment with either factor alone,
and GDNF alone was significantly more effective than ES
alone.
SG morphology in all groups
With cross sections of the cochlea that are used for
counting, it is also possible to evaluate the general mor-
phological features of the SGCs. The micrographs in Fig-
ure 6 show representative sections from the basal turn
(region B) of all four groups. The best preservation of
number and morphological features of the neurons was
seen in the GDNF/ES group (Fig. 6D). SGCs in control
(deafened and nontreated) ears appeared shrunken, and
the spaces between cells in Rosenthal’s canal were larger
than normal in control ears (Fig. 6A). SGCs in treated
Fig. 4. Density of SGCs (mean  SD) in each cochlear region in the
left (treated) and right (control) ears in the three experimental
groups: ES group (A), GDNF group (B), and GDNF/ES group (C).
A: The density of surviving SGCs in the treated ears is higher than
that in nontreated ears throughout the counted regions. In regions A,
B, and D, the differences are significant (*P  0.05, **P  0.01).
B: The density of surviving SGCs is significantly higher in GDNF-
treated vs. nontreated ears in all cochlear areas (*P  0.05, **P 
0.01). C: SGC density in the GDNF/ES-treated ears is significantly
higher than the density in nontreated contralateral ears in all co-
chlear regions (*P  0.05, **P  0.01).
TABLE 1. Mean eABR Thresholds in Microamperes1
Treatment Day 8 Day 44
GDNF/ES 53.8 ( 22.0) 49.4 ( 13.8)
ES 59.3 ( 15.4) 52.1 ( 10.8)
1Values in parentheses are SD. There are no significant differences between the two
groups, GDNF/ES and ES. There are no differences between prestimulation (day 1) and
poststimulation (day 44) measures.
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groups (Fig. 6B–D) appeared to have a larger diameter
than the control cells. There were also smaller spaces
between cells in the treated groups. The GDNF/ES group
exhibited the largest cells among the different groups. No
differences in nuclear morphology were noted among the
four groups. In animals that received GDNF treatment,
the myelin was more prominent, allowing the distinction
of nerve fibers (Fig. 6C,D).
DISCUSSION
Our findings confirm those of previous studies showing
that both ES and GDNF can enhance SGC survival fol-
lowing deafness when applied singly. They also provide
evidence of a synergy in these effects, with increased SGC
survival when ES and GDNF are applied together. This
raises interesting questions about the underlying mecha-
nisms as well as suggesting new avenues for clinical in-
terventions.
Mechanism of action of GDNF in SGCs
The mechanism of GDNF action in the inner ear is not
well understood. GDNF binds to two receptors. It initially
binds to a glycosyl phosphatidyl inositol (GPI)-linked re-
ceptor, GFR (Durbec et al., 1996; Jing et al., 1996;
Treanor et al., 1996). Once bound, the complex then binds
to the transmembrane tyrosine kinase Ret receptor. In the
cytoplasm, the activated receptor complex induces the
PI3K/Akt and ERK pathways, which have been shown to
play a role in cell survival (Pong et al., 1998; Mograbi et
al., 2001). In addition, GDNF activates the transcription
factor CREB (Feng et al., 1999; Poteryaev et al., 1999;
Fig. 5. Histogram comparing SGC density in all three treatment
groups: ES, GDNF, and GDNF/ES. There are significant differences
between the GDNF/ES group and the ES group (*P  0.05). There are
also differences between the GDNF group and the ES group (*P 
0.05). There are no significant differences in nontreatment (right) ears
among all three groups. Data are mean  SD.
Fig. 6. Cross sections of Rosenthal’s canal in ears receiving 40 mg
EA treatment. A: A control ear (deafened and nontreated) showing a
severe depletion of the SGC population. Neuronal cell bodies are
shrunken, leaving spaces between cells in Rosenthal’s canal. B: SGCs
in the ES group, with better morphological preservation and higher
cell packing density than the control group. C: Representative ear
treated with GDNF demonstrates a well-preserved SGC population
with normal morphological appearance. No spaces are observed in
Rosenthal’s canal. Nerve fibers (myelin) can be identified. D: A nearly
normal complement and morphology of SGCs is seen in the combined-
treatment group. Scale bar  25 m.
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Hayashi et al., 2000). GDNF promotes a rapid phosphor-
ylation of mitogen-associated protein kinase and CREB in
dopaminergic neurons. CREB may regulate transcription
of bcl-2, which suppresses apoptosis and promotes neuro-
nal survival (Finkbeiner and Greenberg, 1998). GDNF has
also been reported to enhance axonal regeneration via a
cAMP-dependent mechanism (Cai et al., 1999) and to pro-
tect dopaminergic neurons by activating the antioxidant
enzyme systems (Chao and Lee, 1999).
GDNF mRNAs have been detected in the developing
OHCs and IHCs, and in the mature IHCs (Ylikoski et al.,
1998). In addition, GFR1 has been detected in SGCs and
in their Schwann cells during development and in adult
animals. GDNF, GFR1, and c-ret mRNA are expressed in
the modiolus (Stöver et al., 2000). The level of Ret expres-
sion in the normal inner ear was rather low; however,
GDNF was clearly identified in SGCs following overex-
pression with Ad-GDNF. Furthermore, it is likely that the
stress associated with ototoxic ablation of hair cells leads
to up-regulation of GDNF (Nam et al., 2000). Additional
pathways or receptors (e.g., GFR2, to which GDNF binds
with lower affinity) may potentially be involved in the
activity of GDNF in SGCs. Further experiments will be
necessary to determine the signaling pathway(s) of GDNF
that protects the SGCs.
Interaction between two or more neurotrophic factors is
also likely to influence the SGCs. For example, it has been
shown that the protective effect of GDNF on axotomized
corticospinal CNS neurons depends on the presence of
BDNF (Giehl et al., 1998). It is therefore possible that
GDNF may influence the SGCs indirectly, via up-
regulation of BDNF expression or other neurotrophic fac-
tors, which, in turn, act on these cells in an autocrine
fashion. Moreover, though it has not yet been shown for
GDNF, BDNF may act as a neurotransmitter and influ-
ence spontaneous activity of neurons, including SGCs (Le-
vine et al., 1995; Li et al., 1998a,b).
Mechanism of ES-mediated SGC protection
The positive influence of ES on SGC survival has been
demonstrated in kittens and guinea pigs (Hartshorn et al.,
1991; Leake et al., 1991; Mitchell et al., 1997). Several
pathways for protection resulting from depolarization are
possible, and one or more may be involved in the effects of
ES in the cochlea. These pathways include: 1) regulation
of Ca2 via L-type voltage-gated Ca2 channel; 2) an
autocrine neurotrophin loop; 3) cAMP production; and 4)
CAM kinase-mediated phosphorylation of CREB, with
subsequent changes in gene expression (Hansen et al.,
2001). In SGC cultures, depolarization elevates cAMP and
results in SGC protection (Hansen et al., 2001). In vivo
experiments have demonstrated that BDNF expression in
SGCs is constitutive and is not increased by electrical
activation (Zha et al., 2001). The influence of ES on ex-
pression of GDNF in vivo is not well characterized. How-
ever, the Akt and ERK signaling pathways do not play a
major role in supporting SGC survival by depolarization
(Hansen et al., 2001).
Several reports suggest that electrical activity elevates
Ca2 concentration, leading to an increase in intracellular
elevation of cAMP, resulting in neuronal extension (Ming
et al., 2001). SGC protection with ES is mediated by the
L-type voltage-gated Ca2 channel in vitro (Hegarty et al.,
1997) and in vivo (Miller, 2001). In vitro, the protective
effects of depolarization require the presence of extracel-
lular Ca2 during stimulation as well as functional L-type
Ca2 channels and appear to be mediated by elevation of
cytoplasmic Ca2 (Hegarty et al., 1997).
Several variable parameters in the ES determine the
extent of the protective influence on SGCs. Among these
parameters are the frequency of stimulation, the amount
of current delivered, and the duty cycle (percentage time
on or off). Comparative studies helped determine optimal
stimulation parameters in kittens (Leake et al., 1991) and
in guinea pigs (Mitchell et al., 1997). The parameters used
for ES in these studies are identical to the optimal stim-
ulation determined in guinea pigs (Mitchell et al., 1997).
However, the strain of guinea pigs used here (Elm Hill)
was different from the Murphy animals used in the Mitch-
ell et al. study. This may explain the slight differences in
protection observed in the ES alone group. In addition,
animals in the present study were stimulated for 1 week
less than those in the Mitchell et al. study. Nevertheless,
the ES parameters are likely to be at or near optimal
levels, resulting in a “saturated” effect on SGC survival.
Mechanism of the enhanced SGC protection
by combined GDNF and ES treatment
Augmentation of the protective effects of depolarization
by neurotrophic factors has been demonstrated in SGCs in
vitro (Hegarty et al., 1997). Our study provides the first
set of data on the combined effects of ES and growth factor
overexpression in SGC in vivo. The data confirm the find-
ings obtained in vitro and demonstrate that combined
treatment (GDNF/ES) significantly enhances SGC sur-
vival in deafferented ears. One important question is
whether GDNF and ES exert their protective effects via a
common signaling pathway. Insofar as we selected electri-
cal stimulation parameters that are optimal (at or near
saturation) for SGC survival, the augmented protection
afforded by GDNF, when compared with the individual
effects of GDNF or ES alone, indicates that GDNF and ES
use somewhat independent pathways in exerting their
protection.
In this study, ES-mediated SGC protection was greatest
in the basal turn, which is consistent with previous work
from our laboratory (Mitchell et al., 1997) and that of
others (Leake et al., 1991). Although GDNF’s protective
effects covered a larger portion of the cochlea, its greatest
protective effects were in the basal cochlea. These obser-
vations likely reflect the distribution of the applied pro-
tective factors along the length of the cochlear duct. The
greater apical extent of protection for GDNF relative to ES
probably is due to diffusion of the GDNF protein from its
site of production in the mesothelial cells of the basal turn
into perilymph at higher cochlear turns or takes place via
the fluid bathing the SGCs in the modiolus. Deeper inser-
tion of the stimulating electrode into the guinea pig co-
chlea would likely shift the region of enhanced protection
by ES more apically.
Combining the implantation surgery with inoculation of
the vector presents a technical challenge. The main possible
complication is leakage of the viral vector from the opening
in the round window used for inserting the electrode. This
problem may account for the greater apical extent of GDNF’s
protective effects when applied alone, compared with the
combination group. In the future, alternative approaches for
inoculation or staggered inoculation-implantation may fur-
ther enhance the protective effect of the combined interven-
tion.
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Our data suggest that GDNF overexpression combined
with ES therapy has a greater influence on SGC survival
than does either single treatment. Based on the saturation
of the protection by ES alone, we suggest that a nonover-
lapping mechanism underlies the influence of ES and
GDNF. However, a partially overlapping mechanism can-
not be ruled out. Based on in vitro experiments with
cultured SGC, the mechanisms for the protective effects of
neurotrophic factors and membrane depolarization are
additive. Depolarization influences neuronal survival in
these cultures via a mechanism that involves Ca2 entry
into the cells via L-type Ca2 channels (Hansen et al.,
2001). The increase in Ca2 activates CAM-kinase, lead-
ing to cell survival. The elevation of intracellular Ca2
may also activate growth factors, which act in an auto-
crine loop and bind to Trk receptors that stimulate cell
survival signals through PI3 pathways. One way by which
ES may increase the responsiveness of SGCs to growth
factors is by enhancing recruitment of growth factor re-
ceptors to the cell surface, as demonstrated in other sys-
tems (Meyer-Franke et al., 1998; Reiriz et al., 2002).
The possibility that ES can directly promote GDNF
secretion should also be considered. Although no data are
available to support or refute this possibility in the inner
ear, data obtained in other systems suggest that depolar-
ization of the cell membrane increases GFR1 and -2
GDNF receptor expression during development (Doxakis
et al., 2000). Several neurotrophic factors have been re-
ported to prevent synaptic fatigue caused by ES (Munson
and McMahon, 1997; Gottschalk et al., 1998). Thus, it is
possible that GDNF may contribute to prevention of fa-
tigue in SGCs.
Effects on myelin
After a deafening by kanamycin and EA, surviving
SGCs have little or no perikaryal myelin. The findings
show that overexpression of GDNF is correlated with en-
hanced preservation of the myelin around the SGCs. This
suggests that GDNF may have an effect on the Schwann
cells and their ability to maintain the myelin sheath
around the neurons. This in turn may help to preserve the
structure and function of SGCs. If true, this finding raises
the possibility that the influence of GDNF on SGCs is, at




Previous studies have shown that the cells most effi-
ciently transduced by the adenoviral vector are the me-
sothelial cells lining the perilymphatic fluid spaces. In this
study, we demonstrated that these cells produce high lev-
els of GDNF. Our observations of markedly enhanced SGC
survival indicate that, in Ad-GDNF-transduced ears,
there was an increased GDNF protein level resulting from
secretion by mesothelial cells into the perilymph. The high
level of GDNF staining in the SGCs indicates that the
protein is internalized after it binds to receptors on these
neurons. The presence of GDNF receptors in the modiolus
has been demonstrated previously (Stöver et al., 2000).
Thus, the influence of GDNF on SGC survival may be via
a paracrine mechanism. The level of GDNF protein immu-
noreactivity qualitatively appeared to be similar through-
out the cochlear spiral. This is consistent with the results
showing GDNF protection in all cochlear turns. The effi-
ciency of gene expression in the basal cochlea is higher,
based on results of experiments using reporter genes, than
in other turns following introduction of the vector into the
scala tympani of the basal turn (Stöver et al., 1999; Yagi et
al., 1999). This may explain the enhanced protection ob-
served in the basal turn compared with the upper turns of
the cochlea. In the contralateral (nontreated) side, only
trace GDNF expression was found. This low level of ex-
pression most likely represents the typical low-level en-
dogenous expression of these molecules in the mature
inner ear (Nam et al., 2000).
Relationship between eABR thresholds
and SGC density
Several factors influence the physiology of the dener-
vated SGC and the performance of cochlear implants. In
the absence of SGCs, electrically evoked action potential
in the ascending auditory pathways cannot be generated
with a cochlear implant. However, with a reasonable sur-
vival of ganglion cells, the density of remaining SGCs has
not always correlated well with the performance of the
cochlear implant (Hall, 1990; Incesulu and Nadol, 1998).
Therefore, although preserving as many SGCs as possible
is certainly an important goal in enhancing cochlear im-
plant function, it cannot be assumed that the performance
of the SGCs directly correlates with the density. In fact,
our data show a lack of significant difference between the
GDNF/ES group and the GDNF group in eABR thresh-
olds, despite the significant difference in SGC density
between these groups. It is likely that additional growth
factors or other gene products further enhance the physi-
ology of the remaining SGCs.
Gene vs. protein therapy
There are two major ways to introduce a therapeutic
protein (such as a neurotrophic factor) into the inner ear.
One is to infuse the protein itself, and the other is to
introduce a transgene that will promote synthesis of the
protein. Each method has several advantages and disad-
vantages. The main advantage of infusing the protein
itself is the ability to regulate the amount (and therefore
concentration) of the protein in the inner ear fluid and,
depending on the delivery system, to start and stop it at
will. However, unbound protein has the potential for im-
munogenicity and rapid degradation by proteases. Fur-
thermore, although the duration of delivery can be
controlled, logistically delivery cannot be provided indefi-
nitely, though prolonged infusions are possible using os-
motic pumps. The use of gene therapy involves the intro-
duction of the gene into cells that are then expected to
secrete the gene product. The main advantage of this
method is the continuous production and secretion of the
protein over a period of weeks and perhaps months. As
vectors that shuttle genes into tissues improve, it may also
become possible to regulate the level of gene expression by
using dietetically regulated promoters. Although the use
of viral vectors involves the risk of cytotoxicity or immune
response, future vectors will, it is hoped, benefit from
improved technology that will eliminate these problems.
Implication of combined therapy
in clinical use
In addition to the insight that they provide regarding
the mechanism of action of ES and GDNF on SGC sur-
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vival, these data are also important from a clinical stand-
point. The cochlear implant can provide significant bene-
fits to people with profound hearing impairment.
However, there is great variability in clinical outcome,
and, even with the best outcome, there is clearly room for
improvement in the quality of hearing. Several factors
influence the degree of success of the cochlear implant
procedure, presumably including the number of surviving
SGCs and the health (responsiveness) of the surviving
SGCs. The ability to influence SGC survival and health
can influence the benefits of the cochlear implant. The
evidence from our study that combined intervention with
ES and neurotrophic factors will further enhance the sur-
vival of SGCs raises at least three important challenges
for eventual clinical intervention. First, it will be impor-
tant to determine optimal conditions for ES in combina-
tion with neurotrophic factors. Second, it will be impor-
tant to test other neurotrophic factors, which have been
shown to enhance SGC survival following deafness, such
as BDNF and NT-3, in combination with ES. Finally, it
will be important to determine the best method of neuro-
trophic factor application and the technical feasibility of
combining electrical cochlear implantation with growth
factor therapy. The use of miniosmotic pumps to infuse
protein, in addition to the insertion of the electrode into
the inner ear, may pose a technical challenge and may be
a source of additional risk for cochlear implant recipients.
Alternative methods involving ex vivo gene transfer com-
bined with the cochlear implant may prove to be less risky
and more efficient. Finally, it is reasonable to suggest that
these findings of an additive effect of ES and GDNF in
promoting survival of deafferented auditory nerve cells
likely also apply to deafferented neurons in other parts of
the nervous system. If this is so, these findings have
important implications for our understanding and poten-
tial treatment of neuronal cell death from neurodegenera-
tive disease, neuronal stress, and perhaps aging in the
nervous system.
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Stöver T, Nam Y, Gong TL, Lomax MI, Altschuler RA. 2001. Glial cell
line-derived neurotrophic factor (GDNF) and its receptor complex are
expressed in the auditory nerve of the mature rat cochlea. Hear Res
155:143–151.
Sutton D. 1983. Cochlear implant effects on the spiral ganglion. Ann Otol
Rhinol Laryngol 92:316.
Suzuki M, Yagi M, Brown JN, Miller AL, Miller JM, Raphael Y. 2000.
Effect of transgenic GDNF expression on gentamicin-induced cochlear
and vestibular toxicity. Gene Ther 7:1046–1054.
Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD,
Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A,
Moore MW, Buj-Bello A, Davies AM, Asai N, Takahashi M, Vandlen R,
Henderson CE, Rosenthal A. 1996. Characterization of a multicompo-
nent receptor for GDNF. Nature 382:80–83.
Trupp M, Ryden M, Jornvall H, Funakoshi H, Timmusk T, Arenas E,
Ibanez CF. 1995. Peripheral expression and biological activities of
GDNF, a new neurotrophic factor for avian and mammalian peripheral
neurons. J Cell Biol 130:137–148.
Walsh ME, Webster DB. 1994. Exogenous GM1 ganglioside effects on
conductive and sensorineural hearing losses. Hear Res 75:54–60.
Webster M, Webster DB. 1981. Spiral ganglion neuron loss following organ
of Corti loss: a quantitative study. Brain Res 212:17–30.
West BA, Brummett RE, Himes DL. 1973. Interaction of kanamycin and
ethacrynic acid. Severe cochlear damage in guinea pigs. Arch Otolar-
yngol 98:32–37.
Whitlon DS, Szakaly R, Greiner MA. 2001. Cryoembedding and sectioning
of cochleas for immunocytochemistry and in situ hybridization. Brain
Res Brain Res Prot 6:159–166.
Xing S, Furminger TL, Tong Q, Jhiang SM. 1998. Signal transduction
pathways activated by RET oncoproteins in PC12 pheochromocytoma
cells. J Biol Chem 273:4909–4914.
Yagi M, Magal E, Sheng Z, Ang KA, Raphael Y. 1999. Hair cell protection from
aminoglycoside ototoxicity by adenovirus-mediated overexpression of
glial cell line-derived neurotrophic factor. Hum Gene Ther 10:813–823.
Yagi M, Kanzaki S, Kawamoto K, Shin B, Shah P, Magal E, Sheng J,
Raphael Y. 2001. Spiral ganglion neurons are protected from degener-
ation by GDNF gene therapy. JARO 4:315–325.
Ylikoski J, Pirvola U, Virkkala J, Suvanto P, Liang XQ, Magal E, Alts-
chuler R, Miller JM, Saarma M. 1998. Guinea pig auditory neurons are
protected by glial cell line-derived growth factor from degeneration
after noise trauma. Hear Res 124:17–26.
Zha XM, Bishop JF, Hansen MR, Victoria L, Abbas PJ, Mouradian MM,
Green SH. 2001. BDNF synthesis in spiral ganglion neurons is consti-
tutive and CREB-dependent. Hear Res 156:53–68.
360 S. KANZAKI ET AL.
